LLL12

LLL12 is a small molecule, synthetically developed via structure-based drug design, that functions as a highly selective inhibitor of STAT3 (Signal Transducer and Activator of Transcription 3). It binds directly to the phosphoryl tyrosine 705 site within the STAT3 protein, preventing its phosphorylation, nuclear localization, and DNA binding activity. This results in the downregulation of genes regulated by STAT3 that are involved in cancer cell proliferation and survival. LLL12 has shown potent activity in vitro and in vivo against multiple malignancies, notably multiple myeloma, breast cancer, pancreatic cancer, glioblastoma, hepatocellular carcinoma, osteosarcoma, and non-small cell lung cancer. Preclinical studies indicate LLL12 induces apoptosis in cancer cells (including those resistant to other therapies), reduces tumor growth in mouse xenograft models, inhibits cell migration and angiogenesis, and acts synergistically with certain chemotherapeutics (e.g., doxorubicin, gemcitabine). LLL12 demonstrates high selectivity for STAT3 over other STAT proteins and kinases, and exhibits low toxicity on normal human cells.